Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050421 | 0.80 | KDM4E (0.37) | ALOX5KDM4EPKMSLC6A3 | |
| SCHEMBL8683323 | 0.78 | KDM4E (0.43) | KDM4EPKMSLC6A3CYP2D6 | |
| SCHEMBL2593085 | 0.78 | SLC6A3 (0.44) | IDO1TDO2KDM4EPKMSLC6A3 | |
| SCHEMBL8633179 | 0.77 | CYP3A4 (0.40) | KDM4EPKMSLC6A3CYP3A4CYP2D6 | |
| SCHEMBL9026742 | 0.75 | ATM (0.38) | IDO1TDO2KDM4EPKMSLC6A3 | |
| SCHEMBL8634063 | 0.75 | FFAR2 (0.38) | KDM4EPKM | |
| SCHEMBL9050412 | 0.75 | MME (0.34) | KDM4EPKMCYP2D6 | |
| SCHEMBL9025658 | 0.73 | IDO1 (0.38) | IDO1TDO2KDM4EPKMSLC6A3 | |
| SCHEMBL8632721 | 0.73 | ALOX5 (0.33) | ALOX5KDM4EPKM | |
| Hydrochloric Acid SCHEMBL9050222 | 0.73 | ALDH1A1 (0.38) | ALOX5KDM4ESLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712299-A | TREATMENT OF NEURODEGENERATIVE DISORDERS | ASTRA AKTIEBOLAG (SE) | 1998-01-27 | — | — | US | claimed |
| EP-0707574-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | claimed |
| WO-1995001968-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | claimed |
| US-5712299-A | TREATMENT OF NEURODEGENERATIVE DISORDERS | ASTRA AKTIEBOLAG (SE) | 1998-01-27 | — | — | US | disclosed |
| EP-0707574-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001968-A1 | NOVEL (1-PHENYL-1-HETEROCYCLYL)METHANOL AND (1-PHENYL-1-HETEROCYCLYL)METHYLAMINE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | disclosed |